MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026

Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 ...

Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit

Detailed price information for Edesa Biotech Inc (EDSA-Q) from The Globe and Mail including charting and trades.
Hosted on MSN

MiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnerships

Jennifer S. Buell, President and CEO, stated that MiNK continues to be "the most clinically advanced company, industrializing off-the-shelf, invariant natural killer T cells." She emphasized the ...
WDTN

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory ...

--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the ...